Syndax Pharmaceuticals Ownership | Who Owns Syndax Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Syndax Pharmaceuticals Ownership Summary


Syndax Pharmaceuticals is owned by 117.29% institutional investors, 1.28% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 9.99% of SNDX shares. Vanguard Health Care Inv is the top mutual fund, with 3.50% of its assets in Syndax Pharmaceuticals shares.

SNDX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSyndax Pharmaceuticals117.29%1.28%-18.57%
SectorHealthcare Stocks 42.52%10.81%46.67%
IndustryBiotech Stocks 45.18%10.75%44.06%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de8.63M9.99%$132.70M
Kynam capital management, lp8.52M9.87%$131.08M
Blackrock7.91M9.28%$162.33M
Goldman sachs group5.49M6.35%$84.41M
Vanguard group5.14M5.95%$79.06M
Point72 asset management4.26M4.93%$65.46M
State street3.85M4.46%$59.29M
Eversept partners, lp3.47M4.02%$53.34M
Adage capital partners gp3.31M3.84%$50.95M
Kingdon capital management2.50M2.90%$38.46M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp8.52M9.76%$131.08M
Lion point capital, lp55.00K4.81%$846.17K
Kingdon capital management2.50M4.77%$38.46M
Catalio capital management, lp1.61M4.59%$24.84M
Aisling capital management lp1.32M4.44%$20.27M
Stempoint capital lp1.37M4.21%$21.02M
Eversept partners, lp3.47M3.68%$53.34M
Prosight management, lp1.00M3.60%$15.44M
Bioimpact capital1.38M3.46%$21.16M
Knott david m jr428.00K2.66%$6.58M

Top Buyers

HolderShares% AssetsChange
Point72 asset management4.26M0.11%2.13M
Adage capital partners gp3.31M0.08%1.88M
Bioimpact capital1.38M3.46%1.38M
Nuveen1.48M0.01%1.21M
Soleus capital management2.01M1.56%920.00K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---2.27M
Orbimed advisors---1.93M
Bvf inc/il---1.88M
Blackrock funding, inc. /de8.63M0.00%-1.83M
Balyasny asset management126.14K0.00%-1.69M

New Positions

HolderShares% AssetsChangeValue
Bioimpact capital1.38M3.46%1.38M$21.16M
Apis capital advisors638.00K2.17%638.00K$9.82M
Ikarian capital333.73K0.52%333.73K$5.13M
Canada pension plan investment board229.60K0.00%229.60K$3.53M
Sector gamma as210.81K0.80%210.81K$3.24M

Sold Out

HolderChange
Tfc financial management-1.00
Nelson, van denburg & campbell wealth management group-13.00
Riggs asset managment-26.00
Svb wealth-27.00
Stephens consulting-30.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20252385.78%101,267,9708.78%1171.01%1236.03%6913.11%
Jun 30, 2025232-101,730,1911.68%1170.86%116-3.33%651.56%
Mar 31, 20252332.19%100,944,7752.97%1170.90%119-7.03%6510.17%
Dec 31, 2024216-5.68%91,955,1243.35%1070.99%119-4.03%58-1.69%
Sep 30, 202422511.39%88,858,8691.79%1040.99%12110.00%59-3.28%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv2.99M3.50%-
Vanguard US Total Market Shares ETF2.60M3.01%4.69K
Vanguard Total Stock Mkt Idx Inv2.56M2.98%-56.87K
iShares Russell 2000 ETF2.06M2.39%-
SPDR® S&P Biotech ETF1.54M1.78%3.43K
Eventide Healthcare & Life Sciences I1.41M1.64%236.02K
Franklin Biotechnology Discv A(acc)USD1.02M1.18%-
Vanguard Institutional Extnd Mkt Idx Tr935.83K1.09%-408.69K
Belfius Equities Cure C Cap925.33K1.07%250.25K
Fidelity Small Cap Index854.73K0.99%23.11K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 08, 2025Metzger Michael A Chief Executive OfficerSell$2.58M
Aug 14, 2025Podlesak Dennis-Sell$272.52K
Aug 15, 2025Podlesak Dennis-Sell$298.41K
Aug 18, 2025Podlesak Dennis-Sell$304.17K
Jul 16, 2025Goldan Keith A. Chief Financial OfficerSell$12.03K

Insider Transactions Trends


DateBuySell
2025 Q3-6
2025 Q24-
2025 Q1-4
2024 Q21-
2024 Q1--

SNDX Ownership FAQ


Who Owns Syndax Pharmaceuticals?

Syndax Pharmaceuticals shareholders are primarily institutional investors at 117.29%, followed by 1.28% insiders and -18.57% retail investors. The average institutional ownership in Syndax Pharmaceuticals's industry, Biotech Stocks , is 45.18%, which Syndax Pharmaceuticals exceeds.

Who owns the most shares of Syndax Pharmaceuticals?

Syndax Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (8.63M shares, 9.99%), Kynam capital management, lp (8.52M shares, 9.87%), and Blackrock (7.91M shares, 9.28%). Together, they hold 29.14% of Syndax Pharmaceuticals’s total shares outstanding.

Does Blackrock own Syndax Pharmaceuticals?

Yes, BlackRock owns 9.28% of Syndax Pharmaceuticals, totaling 7.91M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 162.33M$. In the last quarter, BlackRock increased its holdings by 354.33K shares, a 4.69% change.

Who is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Syndax Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 9.76% of its assets in 8.52M Syndax Pharmaceuticals shares, valued at 131.08M$.

Who is the top mutual fund holder of Syndax Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Syndax Pharmaceuticals shares, with 3.50% of its total shares outstanding invested in 2.99M Syndax Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools